ATIA Life Sciences, in partnership with Cyclica, presents EntheogeniX Biosciences, a biotech company committed to advancing psychedelic research for the development of groundbreaking mental health medicines. With a goal to revolutionize the mental healthcare system, we harness the power of artificial intelligence, computational biophysics, and a data-driven approach to uncover new remedies from desired psychedelics. Our team aims to address the urgent needs of patients suffering from mental health diseases such as depression, bipolar disorder, and schizophrenia.

Fueled by innovation, we combine advanced AI, computational biophysics, and medicinal chemistry platforms to engineer novel treatments optimized for rapid development. Led by CEO Glenn Short, our dedicated team is determined to bridge the gap between the existing mental healthcare system and the requirements of those who truly need help. By signing up for our #InsightNetwork, you can receive weekly updates and be part of the movement that aims to make a significant difference.

Join us on this transformative journey and stay informed about our work by visiting our website or following us on Twitter and LinkedIn